NGX 267

Drug Profile

NGX 267

Alternative Names: AF 267B; NGX-267

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Horizon Pharma; Life Science Research Israel
  • Developer Raptor Pharmaceutical Corp
  • Class Antidementias; Nootropics; Piperidines; Small molecules; Spiro compounds; Thiazolidines
  • Mechanism of Action Amyloid beta-protein inhibitors; Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Cognition disorders; Xerostomia

Most Recent Events

  • 03 Nov 2009 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
  • 03 Nov 2009 Discontinued - Phase-I for Cognition disorders in Belgium (PO)
  • 03 Nov 2009 Discontinued - Phase-II for Xerostomia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top